<DOC>
	<DOCNO>NCT01835054</DOCNO>
	<brief_summary>Mitral regurgitation ( MR ) one frequent valve lesion , North America Europe , prevalence increase age population . Organic Mitral Regurgitation ( OMR ) Ischemic Mitral Regurgitation 2 main category MR. Organic primary MR cause anatomic alteration valvular subvalvular mitral apparatus refers rheumatic MR degenerative MR include mitral leaflet prolapse flail leaflet . In past 20 year , degenerative MR become , far , frequent cause severe MR lead surgery western world . However , best current treatment OMR remain uncertain controversial . We obtain preliminary data show OMR dynamic lesion . Hence , echocardiographic evaluation MR rest , generally perform routine clinical exam , necessarily reflect status MR patient 's daily activity thereby adequately assess risk rapid progression poor outcome patient . The objective study identify independent predictor disease progression outcome patient asymptomatic chronic OMR develop validate novel image circulate biomarkers improve risk stratification therapeutic decision-making process patient chronic asymptomatic primary OMR .</brief_summary>
	<brief_title>Determinants Progression Outcome Mitral Regurgitation</brief_title>
	<detailed_description>Mitral regurgitation ( MR ) one frequent valve lesion , North America Europe , prevalence increase owe age population . There 2 main category MR : Organic Mitral Regurgitation ( OMR ) Ischemic Mitral Regurgitation . Organic primary MR cause anatomic alteration valvular subvalvular mitral apparatus refers rheumatic MR degenerative MR include mitral leaflet prolapse flail leaflet . In past 20 year , degenerative MR become , far , frequent cause severe MR lead surgery western world . However , best current treatment OMR remain uncertain controversial . This , large part , due lack prospective data determinant OMR progression outcome . Furthermore , obtain preliminary data show OMR dynamic lesion . Hence , echocardiographic evaluation MR rest , generally perform routine clinical exam , necessarily reflect status MR patient 's daily activity thereby adequately assess risk rapid progression poor outcome patient . The general objective study thus : identify independent predictor disease progression outcome patient asymptomatic chronic OMR develop validate novel image circulate biomarkers improve risk stratification therapeutic decision-making process patient chronic asymptomatic primary OMR . The specific aim study : ( 1 ) To obtain analyze : ) dynamic change MR severity , pulmonary arterial pressure , LV function exercise ; b ) maximum exercise capacity ; c ) metabolic profile ; ) plasma natriuretic peptide , e ) degree localization myocardial fibrosis measure cardiac magnetic resonance Imaging ( MRI ) ; f ) blood marker myocardial extracellular matrix ( ECM ) turnover ; g ) progression MR severity LV dysfunction follow-up ; h ) occurrence adverse clinical outcome ( i.e . symptom , LV dysfunction , atrial fibrillation ( Holter ECG ) , pulmonary hypertension , heart failure , cardiovascular death ) follow-up series 440 patient least moderate OMR symptom baseline . ( 2 ) To analyze valve tissue sample explanted patient undergo mitral valve repair quadrangular resection follow-up order document presence lipid , inflammation , expression metalloproteinases ( MMPs ) . ( 3 ) To obtain analyze postoperative change LV geometry function , pulmonary arterial pressure , symptom , exercise capacity subset patient undergo mitral valve surgery follow-up . ( 4 ) To evaluate usefulness exercise induce change MR severity , pulmonary arterial pressure , LV function ( i.e . contractile reserve ) , blood level natriuretic peptide ECM biomarkers prediction rapid progression LV dysfunction adverse event . ( 5 ) To examine relationship metabolic abnormality link visceral obesity progression outcome OMR . ( 6 ) To determine , among baseline clinical , echocardiographic , MRI , metabolic , biomarkers variable , independently associate progression MR severity LV dysfunction , occurrence adverse clinical outcome patient OMR .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Age &gt; 18 21 year ( Legal age accord country involve study ) Presence least moderate chronic OMR define ERO ≥20mm2 and/or regurgitant volume ≥30mL MR due ischemic heart disease cardiomyopathy &gt; mild mitral stenosis , aortic regurgitation , aortic stenosis pulmonary stenosis previous valve operation history myocardial infarction angiographycally document coronary stenosis congenital pericardial heart disease endocarditis contraindication inability exercise pregnancy Class I II indication mitral valve operation accord 20062007 ACC/AHA/ESC guideline Typical contraindication contrastenhanced MRI ( surgery last 3 month , defibrillator , pericardial electrode , brain surgery , aneurysm clipping , neurostimulator , electric stimulation device magnetically activate , cochlear implant , insulin pump medication delivery device , SwanGanz catheter )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mitral regurgitation</keyword>
	<keyword>Mitral valve prolapse</keyword>
	<keyword>Echocardiography , Doppler</keyword>
	<keyword>Stress echocardiography</keyword>
	<keyword>Cardiopulmonary exercice test</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Cardiac neurohormone</keyword>
	<keyword>Visceral obesity</keyword>
	<keyword>Cardiometabolic risk</keyword>
	<keyword>Risk stratification</keyword>
</DOC>